Production Begins at AbdiBio

Abdi İbrahim, the leader of Turkey's pharmaceutical sector that has been continuing its operations for 106 years with the mission of improving the lives it touches, has officially opened AbdiBio, Turkey's largest biotechnology pharmaceutical production facility.

At the ceremony, in addition to the opening of AbdBio completed with an investment of TRY 400 million, the groundbreaking was also held for Sterile Injectable and Oncology Production Facilities to be realized with an investment of TRY 600 million.

In his speech, Nezih Barut stated that AbdiBio would play a role in reducing imports of biotechnology products and increasing exports, and would also serve as medicine for the current account deficit. "The total investment amount of our Esenyurt production complex is TRY 2.5 billion. Together with our foreign investments, this figure has reached TRY 3 billion.

Our greatest desire is to serve the development of our sector and, most importantly, to repay our debt to the land where we were born and raised. As a company, we measure our value by our contribution to our country.

With this belief, just as we have done until today, we will continue to add value to both our company and our country's economy by making more investments, producing more, achieving more exports, and creating more employment," he said.

Abdi İbrahim, which has been working passionately for 106 years with innovative products and services, bold and pioneering initiatives to improve the lives it touches, opened AbdiBio, a biotechnology pharmaceutical production facility realized with an investment of TRY 400 million, with the attendance of Bursa Deputy and former Minister of Labour and Social Security Dr. Mehmet Müezzinoğlu, President of the Turkish Medicines and Medical Devices Agency Dr.

Hakkı Gürsöz, Abdi İbrahim Chairman of the Board Nezih Barut, Vice Chairman Nesrin Barut Esirtgen, Board Member Ahmet Kamil Esirtgen, Executive Board and Board Member Cenan Esirtgen, Esenyurt Mayor Ali Murat Alatepe and prominent figures from the business world.

AbdiBio, built on a total of 13 thousand square meters of enclosed space and operating with annual production capacity of 11 million vials, 9 million syringes, 22 million cartridges and 1 million lyophilized units, has the distinction of being Turkey's largest biotechnology pharmaceutical production facility.

At the ceremony where AbdiBio, completed with an investment of TRY 400 million, was officially opened, the groundbreaking was also held for Sterile Injectable and Oncology Production Facilities to be realized with a total investment of TRY 600 million.

Nezih Barut: "We Are Witnessing a Historic Moment for Our Country and Sector"

Speaking at the opening ceremony of AbdiBio, Chairman of the Board Nezih Barut, said that as one of Turkey's most established industrial establishments, they continue to make investments that add value to the pharmaceutical sector and Turkey's economy.

Barut, noting that he is proud to lay the foundation for two new investments, the Sterile Injectable and Oncology Production Facilities, together with the opening of AbdiBio, stated, "As Abdi İbrahim, through our bold initiatives, our responsibility to our country and our passion for our work, we have become a company that leads the pharmaceutical sector and always raises the bar.

Believing in the potential of the Turkish pharmaceutical sector on whose foundation our expenditure lies, the strength of our country and its future, we have continuously increased our investments and will continue to do so. AbdiBio is a great work that demonstrates this belief of ours," he said.